Tesla, Inc.'s Q2 deliveries missed targets, but low expectations and Musk-driven sentiment keep the stock strong. Click for ...

Now, it’s worth noting Stock Advisor’s total average return is 1,069% — a market-crushing outperformance compared to 177% for ...

Oracle shares have lifted nearly 21% year to date, sharply outpacing light gains of 1.6% by the Nasdaq composite.

The iShares Preferred and Income Securities is a low-cost ETF offering broad exposure to U.S. preferred securities and a ...

The S&P 500 and Nasdaq reached record closing highs on Monday, capping their best quarter in over a year as hopes for trade deals and possible rate cuts eased investor uncertainty.

US trade talks restart and the Senate votes on One Big Beautiful Bill amendments. S&P 500, Nasdaq notch record highs.

The S&P 500 and Nasdaq notched record high closes on Friday for the first time in months, rebounding from a slump caused by U ...

The second quarter of 2025 may see the Nasdaq Composite (NASDAQINDEX: ^IXIC) achieve a rare feat if it continues to climb ...

By investing $250 a month into this ETF, you could grow your position in it to $923,000 in 30 years. Further, this investment could produce almost $37,000 in annual dividend income at that value.

Shares of CRISPR Therapeutics have risen 9% year to date against the industry ’s 1% decline, as seen in the chart below. The stock has also outperformed the sector and the S&P 500 Index.

Though BB stock is trading at a discount with a trailing 12-month price/book multiple of 3.43 compared with the industry’s multiple of 6.34, this could mean more risk than opportunity.

ZRS Chart of the Month June 06, 2025 — 03:13 pm EDT Written by John Blank for Zacks -> ...